"Sofosbuvir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.
| Descriptor ID |
D000069474
|
| MeSH Number(s) |
D03.383.742.686.850.877.500 D13.695.740.850.877.500 D13.695.827.919.877.500
|
| Concept/Terms |
Sofosbuvir- Sofosbuvir
- 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester
PSI 7977- PSI 7977
- 7977, PSI
- PSI7977
- PSI-7977
|
Below are MeSH descriptors whose meaning is more general than "Sofosbuvir".
Below are MeSH descriptors whose meaning is more specific than "Sofosbuvir".
This graph shows the total number of publications written about "Sofosbuvir" by people in this website by year, and whether "Sofosbuvir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sofosbuvir" by people in Profiles.
-
Kouris G, Hydery T, Greenwood BC, Lavitas P, Price M, Clements K, Alper CJ, Lenz K, Jeffrey PL. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population. J Manag Care Spec Pharm. 2018 Jul; 24(7):591-597.
-
Lu CY, Zhang F, Golonski N, Lupton C, Jeffrey P, Wagner AK. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015. Value Health. 2018 06; 21(6):692-697.
-
Spooner LM, Abraham GM. Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case. Am J Health Syst Pharm. 2017 04 15; 74(8):555.
-
Theodoropoulos N, Whitson BA, Martin SI, Pouch S, Pope-Harman A. Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient. Transpl Infect Dis. 2017 Apr; 19(2).
-
Smith HL, Chung RT, Mantry P, Chapman W, Curry MP, Schiano TD, Boucher E, Cheslock P, Wang Y, Molrine DC. Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study. J Viral Hepat. 2017 03; 24(3):197-206.
-
Thokala P, Simpson EL, Tappenden P, Stevens JW, Dickinson K, Ryder S, Harrison P. Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective. Pharmacoeconomics. 2016 08; 34(8):741-50.
-
Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S, Chandraker A, Heher EC, Elias N, Riella LV. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. PLoS One. 2016; 11(7):e0158431.
-
Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, Steele D, Thiim M, Williams WW, Hashemi N, Kim AY, Thadhani R, Chung RT. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016 Feb; 63(2):408-17.
-
Punzalan CS, Barry C, Zacharias I, Rodrigues J, Mehta S, Bozorgzadeh A, Barnard GF. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant. Clin Transplant. 2015 Dec; 29(12):1105-11.
-
Fantasia HC. Emerging options for treating hepatitis C infection. Nurs Womens Health. 2015 Apr-May; 19(2):183-7.